Predict your next investment

Corporation
HEALTHCARE | Biotechnology
ovascience.com

See what CB Insights has to offer

Founded Year

2011

Stage

IPO | IPO

Total Raised

$46.63M

Date of IPO

11/12/2012

Market Cap

0.07B

Stock Price

9.90

About OvaScience

OvaScience is a fertility company focused on the discovery, development and commercialization of treatments for infertility. OvaScience is working to improve the treatment of female infertility based on technology licensed from Massachusetts General Hospital.

OvaScience Headquarter Location

215 First Street Suite 240

Cambridge, Massachusetts, 02142,

United States

Latest OvaScience News

Dr. David Sinclair Joins Levels as Advisor

Oct 12, 2021

(Photo: Business Wire) October 12, 2021 09:00 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )-- Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor . Dr. Sinclair is a Professor in the Department of Genetics and the co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. Dr. Sinclair has been at the forefront of the latest discoveries in understanding why we age and how to slow its effects. He earned a Ph.D. in Molecular Genetics at the University of New South Wales, Sydney. Dr. Sinclair joins an unprecedented group of thought leaders, clinicians, and researchers in metabolic health, and his expertise will help to drive awareness to the metabolic health crisis through content development and research in partnership with the Levels team. “I’m excited to work with Levels Health to empower people with the tools to optimize their bodies and help achieve longer healthspans and lifespans,” says Dr. Sinclair. “Levels provides customers with insights into how their bodies are functioning—a requisite internal dashboard, as it were—to make better informed decisions about nutrition, sleep, and exercise, because you can’t optimize what you don’t measure.” Dr. Sinclair is the co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others, including Inside Tracker and Life Biosciences. He is the author of Lifespan: Why We Age―and Why We Don't Have To. He is also co-founder and co-chief editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freeman’s “Through the Wormhole” and other media. “Dr. Sinclair is not only the leading visionary thinker in the field of longevity,” says Levels co-founder and chief medical officer, Dr. Casey Means, “but he is also one of the best science communicators of our time, making complex biomedical topics accessible through his prolific writing, podcasting, and speaking. Levels shares a vision with Dr. Sinclair for decentralizing healthcare such that people are able to understand and track their own bodies and make personalized decisions to optimize their own health and longevity. We are thrilled to work with Dr. Sinclair to create tools that empower individuals to improve their healthy lifespan and thrive.” LEVELS’ SOLUTION TO THE METABOLIC HEALTH CRISIS More than 128 million Americans have prediabetes or diabetes. Of the 34 million people with diabetes, 25% don’t know they have it . Of the 88 million people with prediabetes, 90% of them don’t know they have it . Levels’ mission is to solve the metabolic health crisis by tracking glucose in real-time and providing granular visibility into how diet and lifestyle choices affect health. In the same way fitness trackers quantify physical activity and exercise, Levels measures the impact of one's diet and lifestyle on metabolic health by pairing continuous glucose monitoring (CGM) technology with intelligent software. The month-long Levels program includes two 14-day CGM sensors and access to the Levels app, which provides real-time analysis on how food, exercise, and other lifestyle decisions are impacting your health. Currently in closed beta, Levels has a 120,000+ person waitlist. ABOUT DR. DAVID SINCLAIR David A. Sinclair, Ph.D., A.O. was recruited to Harvard Medical School where he has been teaching aging biology and translational medicine for aging for the past 16 years. His research has been primarily focused on the sirtuins, protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction (CR) with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer. The Sinclair Lab was the first one to identify a role for NAD+ biosynthesis in regulation of lifespan and first showed that sirtuins are involved in CR in mammals. They first identified small molecules that activate SIRT1 (such as resveratrol) and studied how to improve metabolic function using a combination of genetic, enzymological, biophysical and pharmacological approaches. Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freeman’s “Through the Wormhole” and other media. He is an inventor on 35 patents and has received more than 25 awards and honors including the CSL Prize, The Australian Commonwealth Prize, Thompson Prize, Helen Hay Whitney Postdoctoral Award, Charles Hood Fellowship, Leukemia Society Fellowship, Ludwig Scholarship, Harvard-Armenise Fellowship, American Association for Aging Research Fellowship, Nathan Shock Award from the National Institutes of Health, Ellison Medical Foundation Junior and Senior Scholar Awards, Merck Prize, Genzyme Outstanding Achievement in Biomedical Science Award, Bio-Innovator Award, David Murdock-Dole Lectureship, Fisher Honorary Lectureship, Les Lazarus Lectureship, Australian Medical Research Medal, The Frontiers in Aging and Regeneration Award, Top 100 Australian Innovators, and TIME magazine’s list of the “100 most influential people in the world”. ABOUT LEVELS HEALTH Levels makes it easy for people to see how their diet affects both their health and their lifestyle in a quantifiable way by measuring biomarkers in real time. We are expanding access to continuous glucose monitoring and making it mainstream, focused on people looking to find their optimal diet and improve their metabolic fitness . Our customers are losing weight , optimizing exercise performance , and developing ideal versions of their dietary philosophy of choice. Casey Means MD (Stanford), Josh Clemente (SpaceX, Hyperloop), Sam Corcos (CarDash, YC), David Flinner (Google), and Andrew Conner (Google) founded Levels to reverse the trend of metabolic dysfunction. Almost 10% of the United States is diabetic and that number is increasing at an increasing rate—88 million Americans are prediabetic and 70% will be diabetic within 10 years. We're starting with the performance and athletic market to build brand credibility and thought leadership and moving into mainstream health and wellness in 2021. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OvaScience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OvaScience is included in 1 Expert Collection, including Women's Health & Wellness.

W

Women's Health & Wellness

960 items

Startups focused on providing products and services catering to women's health and wellbeing.

OvaScience Patents

OvaScience has filed 7 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • RNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/6/2016

2/14/2017

Molecular biology, Monoclonal antibodies, RNA, Genetics, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/6/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/14/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Monoclonal antibodies, RNA, Genetics, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

OvaScience Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OvaScience Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.